Table 3.

Association between NAFLD and subclinical hypothyroidism (gender stratification).

	Men		Women
	OR (95% CI)	p-Value	OR (95% CI)	p-Value
Crude	2.07 (1.00–4.31)	0.051	1.09 (0.63–1.86)	0.764
Model 1	1.93 (0.94–3.98)	0.074	0.99 (0.56–1.73)	0.957
Model 2	1.92 (0.94–3.90)	0.073	1.00 (0.57–1.78)	0.980
Model 3	2.25 (1.07–4.72)	0.033	1.01 (0.57–1.80)	0.967
Model 3–1	2.14 (1.03–4.46)	0.043	1.04 (0.60–1.78)	0.893
Model 3–2	1.93 (0.94–3.94)	0.0072	1.01 (0.57–1.78)	0.980
Model 3-3	1.92 (0.94–3.93)	0.072	1.02 (0.57–1.80)	0.959
Model 3–4	2.06 (0.97–4.35)	0.059	1.01 (0.57–1.78)	0.983
Model 3–5	2.04 (0.98–4.24)	0.056	1.03 (0.58–1.82)	0.917
Model 4	2.37 (1.09–5.12)	0.029	0.98 (0.55–1.76)	0.945

Model 1; adjusted by age.

Model 2; Model 1 + smoking, physical activity, and income.

Model 3; Model 2 + metabolic syndrome.

Model 3–1; Model 2 + waist circumference ≥90 cm in males and ≥80 cm in females.

Model 3-2; Model 2 + elevated triglyceride ≥150 md/dL.

Model 3–3; Model 2 + high-density lipoprotein-cholesterol <40 mg/dL in males and <50 mg/dL in females.

Model 3–4; Model 2 + systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg.

Model 3–5; Model 2 + elevated fasting glucose ≥100 mg/dL.

Model 4; Model 3 + urine iodine and TPOAb.

TPOAb, thyroid peroxidase antibodies.